Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DME
Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase 3 DIAMOND-1 trial and 40% in the DIAMOND-2 trial, according to Oculis.
The DIAMOND (DIAbetic Macular edema patients ON a Drop) program includes two phase 3, double-masked, randomized, multicenter trials aimed at providing a noninvasive treatment option for patients with DME. OCS-01, if successful, could become the first topical eye drop therapy for this condition.
“The results from Stage 1 of the DIAMOND phase 3 trials are highly encouraging," said Arshad M. Khanani, MD, Director of Clinical Research at Sierra Eye Associates who serves as Chairperson of the DIAMOND Program Steering Committee and a member of Oculis’ Board of Directors. "Patients treated with OCS-01 demonstrated significant improvements in visual acuity and a clinically meaningful reduction in macular edema. As the first potential noninvasive topical treatment for DME, OCS-01 offers hope to millions of patients globally.”
Oculis also announced the expansion of the DIAMOND program committees, bringing together retina specialists to provide strategic oversight and guidance. The panel includes:
- Arshad Khanani, M.D.
- David Almeida, M.D.
- Mark Barakat, M.D.
- Kirk Bateman, M.Sc.
- David Boyer, M.D.
- Margaret Chang, M.D.
- Saradha Chexal, M.D.
- Carl Danzig, M.D.
- Dilsher Dhoot, M.D.
- Diana Do, M.D.
- Frank Holz, M.D.
- Baruch D. Kuppermann, M.D.
- Timothy Lai, M.D.
- Anat Loewenstein, M.D.
- Sabri Markabi, M.D.
- Patricio Schlottmann, M.D.
- Ashish Sharma, M.D.
- Veeral Sheth, M.D.
- Michael Singer, M.D.
- Thomas Wolfensberger, M.D.
For more details on the DIAMOND program and committee members, visit oculis.com. Information about the ongoing phase 3 trials can be found at diamondtrial.com.